yasmin 24/4

Yasmin 24/4 3 mg/0.2mg 28 comprimidos | Superama a domicilioMain menu Ads GynecologyYASMIN / YASMIN 24/4 You are hereContact us What is the Yasmin / Yasmin 24/4 medicine for? Useful as a contraceptive for women who have symptoms resulting from the retention of hormone fluids. Treatment of moderate vulgar acne in women who choose Use oral contraception. Treatment of symptoms of premenstrual dysphoric disorder in women who choose Use Hormonal Contraception AVANCE How is Yasmin/Yasmin medication taken 24/4? One released for 28 consecutive days. What does Yasmin / Yasmin medication contain 24/4?Godpirenone, Etinilestradiol. Drospirenona 3 mg/Etinilestradiol 0.02 mg (Régimen 24/4):Each color contains: Drospirenona........................ Etinilestradiol... 0.02 mg (such as etinilestradiol beta-cyclodextrine clatrate) Excipient cbp................................. 1 Each of the whites contains: Excipient cbp................................................... Drospirenona 3 mg/Etinilestradiol 0.02 mg (flex extended regimen): Each color cold contains: Drospirenona.............................. Etinilestradiol... 0.02 mg (such as etinilestradiol beta-cyclodextrine clatrate) Excipient cbp............................................................ Drospirenona 3 mg/Etinilestradiol 0.03 mg:Each contains: Drospirenona............... Etinilestradiol..................... 0.03 mg Excipient cbp............................................................... Drospirenona 3 mg/Etinilestradiol 0.02 mg: Combined oral contraceptive (AOC). With beneficial antimineralocorticoid and antiandrogen effects for women who have symptoms resulting from the retention of hormone fluids. Treatment of moderate vulgar acne in women who choose to use oral contraception. Treatment of symptoms of premenstrual dysphoric disorder (PMD) in women who choose to use hormonal contraception. Drospirenona 3 mg/Etinilestradiol 0.03 mg: Combined oral contraceptive (AOC). With beneficial antimineralocorticoid and antiandrogen effects for women who have symptoms resulting from the retention of hormone fluids and for women with acne and seborre. Combined oral contraceptives (AOCs) should not be used in the presence of any of the following conditions. If any of these conditions appeared for the first time during the use of AOC, the product must be immediately suspended. Drospirenona 3 mg/Etinilestradiol 0.02 mg (Régimen 24/4):Summary of the safety profile: The most frequently reported negatives with Yasmin, when used as oral contraceptives or in the treatment of moderate vulgar acne in women who choose to use oral contraception, are nausea, breast pain, unexpected uterine bleeding and bleeding from the genital apparatus without more specification. They were presented in ≥ 3 % of users. The most frequently reported adverse events with Yasmin, when used for treating ADHD in women who choose to use oral contraception, are nausea, breast pain, and unexpected uterine bleeding. They were presented in ≥ 10% of the users. Serious adverse events are arterial and venous thromboembolism. Tabulated list of adverse events: The frequencies of EA reported in clinical trials with Yasmin as oral contraceptives and in the treatment of moderate vulgar acne in women who choose to use oral contraception (N=3565), as well as in the treatment of the symptoms of ADHD in women who choose to use oral contraception (N= 289) are summarized in the table below. Adverse events are presented in decreasing order of gravity within each frequency group. Frequencies are defined as frequent (≥ 1/100 to 1/10), rare (≥ 1/1,000 to 1/100) and rare (≥ 1/10.000 to 1/1,000). Additional EAs identified only during pharmaco-vigilance, and for those who could not estimate the frequency, are exposed as "unknown". Type of organ or system (MedDRA version 12.1) Frequent (≥ 1/100 to (Section 1/10) Frequent (≥ 1/1,000 a " , " Rare (≥ 1/100,000 a 1/1,000) Unknown Psychiatric disorders Emotional weakness, Depressive depression/humor Decrease or loss of the libidob Nervous system disorders Migraine Vascular disorders Arterial and venous thromboembolic events* Gastrointestinal disorders Nausea Disorders of the skin and tissue subcutaneous Multiform erythema Disorders of the player and of the breast Breastache, Uterine bleeding inquiring, Blessing of genital appliances more specification Type of organ or system (MedDRA version 12.1)Frequents (≥ 1/100 to Frequent (≥ 1/1,000 a Rare (≥ 1/100,000 a UnknownPsychiatric treats Emotional weakness, Depression/depressant smokeDecrease or loss of the libidob Disorders of the nervous system Migraine Vascular disorders Arterial and vein thromboembolic events* Gastrointestinal disorders Nausea Disorders of the skin and tissue subcutaneous Multiform ErythemeSuits of the player and breast pain, breast pain, Uterine bleeding inquiring, Blessing of genital appliances more specification The adverse events in clinical trials were encoded using the MedDRA dictionary (version 12.1). The different terms of MedDRA that represent the same doctor have been grouped as unique adverse events to avoid diluting or masking the true effect.* - Estimated frequency of epidemiological studies including a contraceptive or combined group. The frequency was at the limit with rare. - The following medical entities are summarised in the "Blinth and Veal Thromboembolic Events": Embolia, thrombosis and occlusion Deep Perifous/Infarction, embolism, thrombosis and pulmonary occlusion vascular/Miocardial infarction/Brain stroke and unspecified stroke as hemorrhagic.a The incidence of tests evaluated by TDPM was very common √10/100 b The incidence in trials evaluating the DBPM was Frequent ≥1/100For arterial and venous thromboembolic events and migraine see also the sections "Contraindications", "General precautions". The term preferred by MedDRA is used to describe a certain reaction and its synonyms and related conditions. The representation of the term of EA is based on the MedDRA version 12.1. Drospirenona 3 mg/Etinilestradiol 0.02 mg (flex extended regimen): Safety Profile Summary: The most frequently reported adverse reactions are nausea and breast pain. They were presented in œ 3% of the users. Serious adverse reactions are arterial and venous thromboembolism, breast cancer and nodular focal hyperplasia. Side event tabular summary: The frequencies of the AE reported in clinical trials with Yaz-Flex (N=2738) are summarized in the table below. Adverse events occur in a decreasing order of severity within each frequency group. Frequencies are defined as frequent (≥ 1/100 a) and rare (≥ 1/10,000 a) 1/1000. Type of organ or system (MedDRA version 12.1) Frequent Rare Benign, malignant and non-malignant neoplasms specified polyps) Breast cancer, hyperplasia Focal nodular Psychiatric disorders Emotional weakness, Depression/Humor depressive, Decrease and Loss of Depressive libido Nervous system disorders Migraine Vascular disorders Tromboembolic events and venous* Gastrointestinal disorders Nausea* Hepatobiliary disorders Acute cholecistitis Disorders of the player and of the breast Breast pain**, Uterine bleeding incipient** and Bleeding of the genital apparatus without further specification Type of organ or system (MedDRA version 12.1)FrequentsRare benign, malignant and non-merciful neoplasms specified polyps) Breast cancer, hyperplasia focal point nodularPsychiatric treats Emotional weakness, Depression/Humor depressive, Decrease and Loss of Depressive libido Disorders of the nervous system Migraine Vascular disorders Thromboembolic events arteries and veins*Gastrointestinal treats Nausea** Hepatobiliary disorders Acute cholecistitisSuiters of the reproductive system and breast pain**, Uterine bleeding incipient** and Bleeding of the genital apparatus without further specification Adverse events in clinical trials were encoded using the MedDRA dictionary (version 12.1). The different terms of MedDRA that represent the same doctor have been grouped as unique adverse events to avoid diluting or masking the true effect.* - Estimated frequency of epidemiological studies including a contraceptive or combined group. The frequency was at the limit with Very rare. - The following medical entities are summarised in the "Blinth and Vey Thrombolic Event": Embolysis, thrombosis and deep vein occlusion/Infarction, embolism, vascular lung thrombosis and occlusion/Myocardial infarction/Brain stroke and unspecified stroke as hemorrhagic # The incidence of trials with Yaz evaluating DBD (N= 289) was very common √10/100 For arterial and vein thromboembolics, breast cancer, nodular focal hyperplasia (benign liver tumors) and migraine see also the sections "Contraindications", "General precautions". MedDRA's preferred term is used to describe a certain adverse event and its synonyms and related conditions. The representation of the terms of the AE is based on MedDRA, version 12. 1Drospirenona 3 mg/Etinilestradiol 0.03 mg:Summary safety profile: The most frequently reported adverse reactions with Yasmin are nausea and breast pain. They were presented in ± 6% of the users. Serious adverse events are arterial and venous thromboembolism. Side event tabular summary: The frequencies of ATS reported in clinical trials with Yasmin (N=4897) are summarized in the table below. Adverse events occur in a decreasing order of severity within each frequency group. Frequencies are defined as frequent (≥ 1/100 a) and rare (≥ 1/10,000 a) 1/1000. Additional EAs identified only during post-marketing studies, and for those who could not estimate the frequency, are exposed as "unknown". Type of organ or system (MedDRA) Frequent (≥ 1/100 (a) Rare (≥ 1/10,000 a) Unknown Psychiatric disorders Emotional weakness Depression/depressant humor Decrease and loss of libido Nervous system disorders Migraine Vascular disorders Tromboembolic events and venous* Gastrointestinal disorders Nausea Disorders of the skin and tissue subcutaneous Multiform erythema Disorders of the player and of the breast Breast pain Unexpected uterine bleeding Bleeding of the genital apparatus without further specification Type of organ or system (MedDRA)Frequent (≥ 1/100 to Raros (≥ 1/10,000 to UnknownPsychiatric treats Emotional weakness Depression/depressant humor Decrease and loss of libido Disorders of the nervous system Migraine Vascular disorders Thromboembolic events arteries and veins* Gastrointestinal disorders Nausea Disorders of skin and tissue subcutaneous Multiform ErythemeSuits of the player and Breast Pain Breast Pain Unexpected Uterine Bleeding of the Genital System without further specification Adverse events in clinical trials were encoded using the MedDRA dictionary (version 12.1). The different terms of MedDRA that represent the same doctor have been grouped as unique adverse events to avoid diluting or masking the true effect.* - Estimated frequency of epidemiological studies including a contraceptive or combined group. The frequency was at the limit with Very rare. - The following medical entities are summarised in the "Blinth and Velocity Thromboembolic Events": Embolia, thrombosis and occlusion Deep Peripheral/Infarction, embolism, thrombosis and pulmonary occlusion vascular/Miocardial infarction/Brain stroke not specified as hemorrhagic for arterial and venous thromboemblic sections and migraine. MedDRA's preferred term is used to describe a certain adverse event and its synonyms and related conditions. The representation of the ADR terms is based on MedDRA, version 12.1. Description of the selected adverse events: The adverse events with very low frequency or with delay of the beginning of the symptoms that are considered related to the combined oral contraceptive group are described below (see also the sections "Contraindications", "General precautions"): Tumors:Other conditions:Drospirenona 3 mg/Etinilestradiol 0.02 mg (flex extended genus): Interactions: Intracyclic bleeding Box with 28 gums (24s in color with Drospirenona 3 mg /Etinilestradiol 0.02 mg and 4 in white). Box with 30 color tablets with Drospirenona 3 mg /Etinilestradiol 0.02 mg. Box with 21 tablets with Drospirenona 3 mg /Etinilestradiol 0.03 mg. How to take Yasmin: If they are taken correctly, contraceptives or combinations have a fee of approximately 1% per year. The fallacy rate may increase in case of oblivion or incorrect take of (Yasmin). Drospirenona 3 mg/Etinilestradiol 0.02 mg (Régimen 24/4): Compresses have to be taken in the order indicated in the system, every day at the same time approximately, with a little liquid if necessary. The taking of thes is continuous. It must be taken daily for 28 consecutive days. Each subsequent installation begins the next day of the last of the previous Tools. Deprivation bleeding usually starts on the 2-3 days after the inerts have started and it may not have ended when the next team is due to start. How to start? Conduct to follow if you forget the taking of some kind: forgotten enerts can be ignored. However, they must be disposed of to avoid unintended prolongation of the inert phase. The following tips only refer to the forgetfulness of the assets: If the user is delayed less than 24 hours in the taking of any assets, the contraceptive protection is not reduced. The woman should take the as soon as she remembers and should take the following at the usual time. If the user is delayed more than 24 hours in the taking of any asset, birth control can be reduced. The guideline, in case of oblivion, may be governed by the following two basic rules: Consequently, in daily practice the following can be advised: If the cold woman forgets and then has no bleeding from deprivation in the inert phase, the possibility of pregnancy should be considered. Tips for Gastrointestinal Disorders: In case of severe gastrointestinal disorders, writing cannot be complete and additional birth control measures must be taken. If vomiting occurs in the 3-4 hours following the taking of the asset, the advice regarding oblivion is applicable, which are collected in the section "Conduct to follow if you forget the taking of the ignition". If the woman does not want to change her normal dess-take scheme, she must take the additional (s) required from another Tools. How to change periods or how to delay periods: To delay a period, women should start the following Yasmin Tools without taking the inerts of the current Tools. The extension may have the duration of women until the end of the second Tools assets. During the extension, a woman may experience intracyclic or stained bleeding. Then the regular take of Yasmin resumes after the des inert phase. To change your periods to a day of the week other than that you have with your current scheme, you may be advised to shorten the next phase of inert ignition, as many days as a. Shorter the interval, greater is the risk that you do not have a deprivation bleeding and will experience intracyclic bleeding and stained during the taking of the second Tools (as when a period is delayed). Drospirenona 3 mg/Etinilestradiol 0.02 mg (flex extended regimen): Every day, at the same time approximately, one should be taken with a little fluid. The air shot is continuous for at least 24 days. During the 25-120 days a woman can decide when to have a 4-day sin interval. A sin interval should not last longer than 4 days. It has been freed from having a 4-day free interval after a maximum of 120 days continuous take-over. After each interval a new cycle of take-ups is started for at least 24 days up to a maximum of 120 days. Normally dry hay during the interval without 4 days and may not have ended before the next one has to be taken. In the case of continuous staining and/or bleeding (three consecutive days) during the 25-120 days, it is advisable to make the interval without 4-day tablets. This will reduce the total number of days of bleeding. How to start? Conduct to follow if you forget taking some kind: If the user is delayed less than 24 hours in taking any, the birth control is not reduced. The woman should take the as soon as she remembers and should take the following at the usual time. If the user is delayed more than 24 hours in taking any, the contraceptive protection can be reduced. The guideline, in case of oblivion, may be governed by the following two basic rules: Consequently, in daily practice the following can be advised: If the cold woman forgets and then has no deprivation bleeding in the next free interval des, the possibility of pregnancy should be considered. Tips for Gastrointestinal Disorders: In case of severe gastrointestinal disorders, writing cannot be complete and additional birth control measures must be taken. If vomiting occurs within 3 to 4 hours following the taking of an ignition, the advice regarding oblivion is applicable, as shown in the section "Conduct to follow if you forget the taking of a tablet". Drospirenona 3 mg/Etinilestradiol 0.03 mg: Loss have to be taken in the order indicated in the system, every day approximately at the same time, with a bit of fluid if necessary. They keep a daily rhythm for 21 consecutive days. Each subsequent installation starts after a 7-day interval without taking, during which a deprivation bleeding usually occurs. This usually starts on the 2-3 days after taking the last, and cannot have ended before starting the next team. How to start? Conduct to follow if you forget taking some kind: If the user is delayed less than 12 hours in taking any, the birth control is not reduced. The woman must take the ignition as soon as she realizes the oblivion and must continue to take the following at the usual time. If the user delays more than 12 hours in the taking of any, the contraceptive protection can be reduced. The guideline, in case of oblivion, may be governed by the following two basic rules: Consequently, in daily practice the following can be advised: If the woman forgets and then has no deprivation bleeding at the first normal interval free of exercises, the possibility of pregnancy should be considered. Tips for Gastrointestinal Disorders: In case of severe gastrointestinal disorders, writing cannot be complete and additional birth control measures must be taken. If vomiting occurs in the 3-4 hours following the tablet's taking, the advice should be followed for the case in which the take has been forgotten that are collected in the section "behavior to follow if you forget the taking of a tablet". If the woman does not want to change her normal dess-take scheme, she must take the additional (s) required from another Tools. How to move periods or how to delay periods: To delay a period, the woman must continue with another Yasmin Tools without leaving the usual interval withouts. The extension may have the duration of women until the end of the second system. During the extension, a woman may experience intracyclic or stained bleeding. Then the regular Yasmin shot resumes after the usual 7-day interval without tablets. To move your periods to a different day of the week than you have them with your current scheme, you may be advised to shorten the next free interval for as many days as from. However, the shorter the interval, the higher the risk that you do not have a deprivation bleeding and will experience intracyclic bleeding and stained during the second Tools (like when a period is delayed). Additional information on special populations: Girls and adolescents: Yasmin is indicated only after the menarquia. There is no data to suggest the need to adjust the dose. Drospirenona 3 mg/Etinilestradiol 0.02 mg (flex extended regimen): Girls and teenagers: Yasmin is indicated only after the menarquia. There is no data to suggest the need to adjust the dose in adolescents. Geriatric patients: It is not appropriate. Yasmin is not indicated after menopause. Patients with liver failure: Yasmin is contraindicated in women with separate liver diseases. See also the sections "Contraindications" and "Paracokinetic properties". Patients with kidney failure: Yasmin is contraindicated in women with kidney failure or acute kidney failure. See also the sections "Contraindications" and "Paracokinetic properties".

IMAGES

Yasmin 24/4 3 mg/0.02 mg - Precio en Farmalisto MX

Yasmin 24/4 t 28

YASMIN 24/4 – Pharma Express

Yasmin, drospirenona, anticonceptivo, grageas, Bayer, RX-ginecologia

Farmacias del Ahorro | Yasmin 24/4 3mg/0.02 mg 28 comprimidos | Tienda en línea a todo México

YASMIN 24/4 - PLM

YASMIN 24/4 3 MG/0.02 MG C/28 COMP.28/TAB

La Comer | Detalle de artículo

Yaz 24 4 - Online Doctor Service | Dokteronline.com

YASMIN 24/4 28 PILLS - MEXIPHARMACY - PHARMACY ONLINE IN MEXICO OF BRAND NAME & GENERIC MEDICATIONS, DRUG STORE IN MEXICO, MEDICINES ONLINE, PHARMACY IN MEXICO / Anointed By God

Yasmin 24 4 28 comprimidos | Farmacias San Pablo

YASMIN 3MG 24/4 CPR C28 – Farmacia Mexicana Buena Salud

YASMIN 24/4 - Galenox.com ¡Tu colega siempre en línea!

Yasmin 24/4 3Mg/0.02Mg | Vitau

YASMIN 24/4 28 PILLS - Farmacia Del Niño - PHARMACY ONLINE IN MEXICO OF BRAND NAME & GENERIC MEDICATIONS, DRUG STORE IN MEXICO, MEDICINES ONLINE, PHARMACY IN MEXICO / Anointed By God

Yaz vs Yasmin: What's the difference? - Pandia Health

Categorias — Alsuper

Yasmin (pastillas anticonceptivas): efectos, dosis, precio y eficacia

Yasmin 24/4 3 mg/0.02 mg - Precio en Farmalisto MX

Yasmin | Pastillas Anticonceptivas [ Guía de Uso y Opiniones ]

全球No.1避孕藥系列 – YAZ®優悅vs Yasmin®優思明

La Comer | Detalle de artículo

TOMAR PASTILLAS ANTICONCEPTIVAS YASMIN 24/4⎢DAY ARVIZU♡ - YouTube

Ontario judge gives green light to Yasmin, Yaz class action lawsuit | Globalnews.ca

Yasmin: Exactly How Safe Is Your Contraceptive Pill? | Marie Claire Australia

Yasmín 3mg/0.03mg 21 Comprimidos

YASMIN - PLM

YASMIN 24/4 28 PILLS - MEXIPHARMACY - PHARMACY ONLINE IN MEXICO OF BRAND NAME & GENERIC MEDICATIONS, DRUG STORE IN MEXICO, MEDICINES ONLINE, PHARMACY IN MEXICO / Anointed By God

Yasmin 24/4 3 mg/0.02 mg - Precio en Farmalisto MX

Oral Contraceptives for the Treatment of Premenstrual Mood Symptoms

Yasmin, YAZ, Ocella Injury Litigation | Nolan Law Group

Yasmin 28 Side Effects - Yasmin birth control side effects

ᐅ ¿Cómo funciona Yasmin 24/4? ⚡️ » Cómo Funciona

Yasmin 24/4 3 mg/0.02 mg - Precio en Farmalisto MX

Yasmin (pastillas Anticonceptivas): Usos, Enseres Secundarios Y Precio - Efectos Secundarios De Las Pastillas Anticonceptivas Yasmin 24/4

Yasmin 24/4 28 gra Mx Compra Al Mejor Precio, Tienda Oficial Bayer

San Pablo Farmacia

YAZ®優悅®VS Yasmin®優思明®

U.S. FDA Approves New Oral Contraceptive That Also Raises Folate Levels

全球No.1避孕藥系列 – YAZ®優悅vs Yasmin®優思明